ASO Splicing Modulators for Timothy Syndrome Exon 8A
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Timothy syndrome type 1, caused by a heterozygous c.1216G>A pathogenic variant in exon 8 A of CACNA1C, leads to abnormal calcium channel function and neuropsychiatric disorders, with current therapies failing to effectively address the underlying splicing defects and cellular phenotypes.
Innovation Solution
Administration of antisense oligonucleotides (ASOs) that modulate the splicing of exon 8 A of CACNA1C, reducing its expression and restoring normal channel function and interneuron migration in human cortical neurons and organoids, both in vitro and in vivo.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for Timothy syndrome, then general symptom management is achieved, but the underlying splicing defects and cellular phenotypes remain unaddressed
Solution Approach 1:
The patent extracts and targets the specific splicing defect (exon 8A inclusion) as the root cause of Timothy syndrome. By using ASOs to specifically bind to and modulate the splicing of exon 8A in the CACNA1C gene, the therapy removes the harmful splicing event while preserving normal channel function, thereby addressing the underlying genetic defect rather than just managing symptoms
Solution Approach 2:
The patent introduces antisense oligonucleotides (ASOs) as intermediary molecules that mediate between the genetic defect and the desired therapeutic outcome. The ASOs serve as mediators that bind to pre-mRNA containing exon 8A and redirect splicing to exclude this exon, thereby converting the splicing defect into a corrected splicing pattern without directly modifying the DNA sequence
2Reliability
If exon 8 A expression is reduced to rescue channel function, then calcium channel inactivation and calcium dynamics are restored, but the mechanism requires novel splicing modulation approaches
Solution Approach 1:
The patent replaces traditional pharmacological approaches (small molecule drugs binding to protein channels) with a nucleic acid-based mechanism (ASOs binding to pre-mRNA). This substitution operates at the RNA splicing level rather than the protein level, enabling correction of the root cause through molecular recognition and splicing modulation rather than through complex drug-channel interactions
3Reliability
If ASOs are administered to modulate CACNA1C splicing, then exon 8 A downregulation and channel function rescue are achieved, but new therapeutic mechanisms must be validated
Solution Approach 1:
The patent employs preliminary validation of the ASO mechanism in cell culture models before clinical application. By first demonstrating that ASOs can successfully modulate CACNA1C splicing and rescue channel function in controlled in vitro systems, the patent establishes a proof-of-concept that simplifies subsequent clinical validation and reduces the complexity of mechanism detection in human patients
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ASOs effectively downregulate exon 8 A expression, rescuing delayed channel inactivation, calcium dynamics, and interneuron migration defects, demonstrating a novel genetic rescue strategy for Timothy syndrome.
Implementation Method 1
antisense oligonucleotides (ASOs) that modulate the splicing of exon 8 A of CACNA1C
Data Source
AI summary
The present disclosure provides methods of treating an individual having Timothy syndrome. Aspects of the methods include administering an effective dose of an agent to the individual, wherein the agent modulates the splicing of an 8 A or an 8 exon of CACNA1C. Also provided are compositions that find use in practicing embodiments of the methods.